Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

NCT05953831 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Transfer of study responsibility and planning

Conditions

Heart Failure With Preserved Ejection Fraction

Interventions

DRUG: CDR132L
DRUG: Placebo

Sponsor

Cardior Pharmaceuticals GmbH